Výsledky vyhledávání - "J. G. M. Segalla"

Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): Results from OCTAVIA

Autor: Octavia Investigators, Ana Oaknin, Daniel Stroyakovsky, Bengt Tholander, J. G. M. Segalla, Frédéric Selle, David T. Bollag, Antonio González-Martín, Laurence Gladieff, An K.L. Reyners, Martin Gore, Nadezhda V. Kovalenko, Sandro Pignata

Publikováno v: Journal of Clinical Oncology. 30:5017-5017

5017^ Background: In two randomized phase III trials in OC (GOG218 and ICON7), front-line BEV + q3w PAC + q3w C followed by BEV alone significantly improved progression-free survival (PFS) vs chemotherapy (CT) alone. In the Japanese NOVEL trial, wPAC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e513e465af202fd4a7232399e44f1f66
https://doi.org/10.1200/jco.2012.30.15_suppl.5017

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání